GleamWall
中文EN

PROF Profound Medical Corp.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1628808 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY65.3%
TTM net income YoY17.4%
TTM EPS YoY295.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin73.9%
Operating margin-145.1%
Net margin-137.5%
FCF margin—
EBITDA margin-143.4%

Returns

ROE-87.0%
ROA-64.7%
ROIC (approx.)-157.1%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets26.9%
Debt / equity0.21x
Current ratio4.54x
Interest coverage-105.79x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.83M$2.48M$5.34M$5.98M$5.29M$2.21M$2.62M$4.18M
Cost of revenue$2.15M$536,000$1.50M$1.99M$1.36M$593,000$768,000$1.21M
Gross profit$7.68M$1.95M$3.83M$3.99M$3.93M$1.62M$1.85M$2.96M
R&D expense$5.81M$5.65M$5.26M$4.27M$5.42M$6.10M$4.81M$4.65M
SG&A expense$9.70M$7.36M$6.59M$7.09M$7.43M$9.33M$8.21M$6.66M
Operating income-$7.82M-$11.07M-$8.02M-$7.37M-$8.91M-$13.81M-$11.17M-$8.35M
Interest expense$80,000$79,000$80,000$85,000$119,000$86,000$104,000—
Pretax income-$7.73M-$9.48M-$7.03M-$8.15M-$7.86M-$15.63M-$10.68M-$5.18M
Income tax-$4,000$55,000$25,000$26,000$121,000$64,000$41,000-$238,000
Net income-$7.72M-$9.54M-$7.05M-$8.18M-$7.98M-$15.70M-$10.72M-$4.95M
EBITDA-$7.70M-$10.94M-$7.93M-$7.31M-$8.82M-$13.70M-$11.05M-$8.19M
EPS (basic)-0.21-0.260.19—-0.26-0.520.36—
EPS (diluted)-0.21-0.260.19—-0.26-0.520.36—
Weighted avg. shares (diluted)36.56M36.35M36.30M—30.10M30.05M30.04M—
Balance sheet
Cash & equivalents$33.34M$38.27M$50.30M$59.72M$24.83M$35.20M$46.43M$54.91M
Inventory$10.24M$10.46M$9.00M$8.24M$8.34M$8.35M$6.79M$5.80M
Current assets$54.83M$58.86M$69.53M$76.09M$41.52M$48.81M$59.91M$69.06M
PP&E, net$430,000$556,000$682,000$698,000$338,000$278,000$309,000$425,000
Intangibles$115,000$121,000$129,000$138,000$123,000$175,000$214,000$261,000
Total assets$58.15M$62.38M$73.46M$77.47M$42.30M$49.67M$60.86M$70.23M
Current liabilities$12.06M$9.11M$10.61M$6.08M$9.94M$5.72M$5.29M$6.57M
Short-term debt$4.51M$4.51M$4.50M—$4.48M——$1.74M
Long-term debt$4.51M$4.51M$4.50M$4.50M$4.48M$4.46M$4.49M$4.66M
Total debt$9.02M$9.01M$9.01M$4.50M$8.96M$4.46M$4.49M$6.40M
Total liabilities$15.64M$12.58M$14.03M$11.04M$10.16M$10.41M$10.07M$9.81M
Shareholders' equity$42.51M$49.81M$59.42M$66.43M$32.14M$39.26M$50.79M$60.42M
Net debt-$24.32M-$29.26M-$41.29M-$55.22M-$15.87M-$30.73M-$41.95M-$48.51M
Shares outstanding36.63M36.53M36.34M36.29M30.19M30.05M30.05M30.04M
Cash flow statement
Operating cash flow-$5.01M-$11.34M-$8.58M-$6.57M-$9.61M-$13.74M-$8.28M-$5.88M
Financing cash flow———$41.43M$0$0-$290,000$35.44M
Depreciation & amortization$126,000$126,000$93,000$62,000$93,000$102,000$116,000$160,000
Stock-based compensation$257,000$874,000$1.05M$1.38M$1.67M$1.45M$989,000$442,000

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.